Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults
Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014;14:159-164.
Free:
http://link.springer.com/article/10.1007%2Fs40268-014-0053-9
Pharmacokinetic and triglyceridelowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies
Braeckman R, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract]. Circulation. 2013;128:A19343.
AMR101, a pureEPA omega3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDLC: the MARINE study
Bays HE, Ballantyne CM, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study [abstract]. J Clin Lipidol. 2011;5:205.
The effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statintreated patients with persistent high triglycerides (200 and <500 mg/dL): the ANCHOR study
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. The effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (≥200 and <500 mg/dL): the ANCHOR study [abstract]. J Clin Lipidol. 2012;6:279-280.